- Sections
- A - Nécessités courantes de la vie
- A61K - Préparations à usage médical, dentaire ou pour la toilette
- A61K 39/095 - Neisseria
Détention brevets de la classe A61K 39/095
Brevets de cette classe: 618
Historique des publications depuis 10 ans
|
56
|
54
|
44
|
42
|
33
|
36
|
27
|
30
|
31
|
14
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Glaxosmithkline Biologicals S.A. | 1596 |
125 |
| Pfizer Inc. | 3374 |
48 |
| Novartis AG | 10340 |
31 |
| The Regents of the University of California | 20594 |
21 |
| Sanofi Pasteur Inc. | 354 |
14 |
| Children's Hospital & Research Center at Oakland | 55 |
13 |
| Serum Institute of India Private Limited | 106 |
13 |
| Griffith University | 161 |
12 |
| Wyeth LLC | 611 |
11 |
| Wyeth Holdings LLC | 51 |
11 |
| MSD Wellcome Trust Hilleman Laboratories Pvt Ltd. | 23 |
9 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2979 |
9 |
| Intravacc B.V. | 29 |
8 |
| The Corporation of Mercer University | 32 |
7 |
| Sanofi Pasteur | 378 |
7 |
| Novartis Vaccines And Diagnostics S.R.L. | 11 |
6 |
| GlaxoSmithKline Biologicals SA | 10 |
6 |
| Immunobiology Limited | 9 |
6 |
| Engineered Antigens Inc. | 15 |
6 |
| Chengdu Olymvax Biopharmaceutical Co.,Ltd | 12 |
6 |
| Autres propriétaires | 249 |